Many genetic diseases exhibit considerable epidemiological comorbidity and common symptoms, which provokes debate about the extent of their etiological overlap. The rapid growth in the number of known disease-causing mutations in the Human Gene Mutation Database (HGMD) has allowed us to characterize genetic similarities between diseases by ascertaining the extent to which identical genetic mutations are shared between diseases. Using this approach, we show that 41.6% of disease pairs in all possible pairs (42, 083) exhibit a significant sharing of mutations (P value < 0.05). These mutation-related disease pairs are in agreement with heritabilitybased disease-disease relations in 48 neurological and psychiatric disease pairs (Spearman's correlation coefficient = 0.50; P value = 3.4 × 10 −5 ), and share over-expressed genes significantly more often than unrelated disease pairs (1.5-1.8-fold higher; P value ≤ 1.6 × 10 −4 ). The usefulness of mutation-related disease pairs was further demonstrated for predicting novel mutations and identifying individuals susceptible to Crohn disease. Moreover, the mutation-based disease network concurs closely with that based on phenotypes.
INTRODUCTION
The co-occurrence of apparently distinct diseases is frequently observed as clinical phenotypic overlaps between different genetic diseases. For example, an increased incidence of attention deficit hyperactivity disorder (ADHD) has been found in families with bipolar disorder (Faraone, Biederman, & Wozniak, 2012) . Patients with Friedreich ataxia appear to be at increased risk of developing type 2 diabetes mellitus (Ristow, 2004) . Type I diabetes and celiac disease often co-exist in populations because of seven common associated loci according to a case-control association study (Smyth et al., 2008) . Inflammatory bowel disease is known to be associated with an increased incidence of psychological disorders such as depressive disorder (Ananthakrishnan et al., 2013) . Such co-occurrences are being increasingly discovered between disease pairs through the statistical analysis of the growing number of large electronic clinical records (Blair et al., 2013; Lee et al., 2008; Park, Lee, Christakis, & Barabasi, 2009 ).
The genetic mechanisms underlying disease co-occurrences are being uncovered by means of increasingly powerful sequencing technologies. In particular, genome-wide association studies (GWAS) are capable of revealing common risk variants that transcend traditional diagnostic boundaries. Examples include high correlations in genetics between migraine and stroke (Debette et al., 2015) , and across psychiatric diseases such as schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (Lee, Ripke, Neale, Faraone, & Purcell, 2013) . Causative mutations associated with multiple diseases have also been discovered through sequencing (Carvill et al., 2013) .
For example, SCN2A gene mutations were found to be associated not only with self-limited autosomal dominant syndrome of benign familial neonatal-infantile seizures but also with epileptic encephalopathies (Carvill et al., 2013; Liao et al., 2010) . In similar vein, CACNA1A gene mutations have been implicated in a range of neurological conditions (Damaj et al., 2015; Jouvenceau et al., 2001; Subramanian, Senthil, & Sujatha, 2015) .
Obviously, shared genetic architecture across different diseases is suggestive of possible common genetic etiologies. Disease interactions inferred from shared genes have often improved our understanding of molecular mechanisms underlying inherited diseases (Davis & Chawla, 2011; Lechner et al., 2012) . Moreover, shared genes have led directly to the identification of pan-cancer driver genes (Melamed, Emmett, Madubata, Rzhetsky, & Rabadan, 2015) and the discovery of common genetic mechanisms of four neuropsychiatric disorders: autism spectrum disorder (ASD), epileptic encephalopathy, intellectual disability, and SCZ (Li et al., 2016) .
However, sharing disease-causing genes does not automatically indicate the identity of the underlying molecular mechanisms because genes (and their protein products) have multiple functions and different mutations may affect different functions and cause different diseases. For example, frameshift and truncating mutations (such as exon 8 IVS+3Ging nisexon 6 549+1delG) in the PRKAR1A gene cause Carney complex due to nonsense-mediated mRNA decay (Kirschner et al., 2000; Sun et al., 2015) , whereas another mutation on the exon 11 (c.1101C > T), was found to cause acrodysostosis by truncating the last 14 amino acids in the coded cAMP-binding protein domain B protein due to the introduction of a stop codon (Linglart et al., 2011) .
Meanwhile, the same genetic mutation can cause different heritable diseases. For example, the c.1932delC mutation in the HPS1 gene has been implicated in both Gitelman syndrome (Maki et al., 2004) and Hermansky-Pudlak syndrome (Wei, Lian, Wang, & Li, 2009) . Similarly, the c.727-1G > T mutation in the KAL1 gene was found to be relevant to both diastrophic dysplasia (Barbosa et al., 2011) and renal agenesis (Tsai & Gill, 2006) , while another de novo mutation (c.1267C > T) in the same gene has been reported to be associated with both epilepsy and ASD (Jiang et al., 2013) . When identical mutations are shared between diseases, it suggests these diseases share molecular mechanisms at least in part. Thus, shared mutations, rather than shared disease-causing genes, might be a more specific and hence more accurate indicator of genetic similarity between diseases.
In this study, we identified disease relationships between inherited human diseases by ascertaining the number of shared genetic mutations. The disease-causing mutations were taken from the Human Gene Mutation Database (HGMD) (Stenson et al., 2003) . The mutations relevant to the genetic diseases were expanded by including mutations associated with their "sub-diseases" as defined by the Human Phenotype Ontology (HPO) project (Kohler et al., 2014) . The resulting relationships identified between brain and psychiatric diseases are consistent with heritability-based studies, and related diseases identified by this mutation-based approach share a significantly greater number of over-expressed genes than unrelated ones. The mutation-based approach was shown to be useful for the discovery of novel disease-causing mutations and the identification of patients with Crohn disease. Moreover, the mutation-based disease network was shown to be consistent with phenotypic clusters. These results highlight the potential importance of using mutations to detect diseasedisease relationships.
METHODS

HGMD dataset
We obtained 157,581 disease-causing mutations (including single base-pair substitutions and micro-insertions/deletions) from the HGMD (HGMD Professional v.2015.4) (Stenson et al., 2003) . In order to obtain a hierarchical definition of diseases, we mapped the "Cui" ID (defined by Unified Medical Language System, UMLS) of the diseases annotated in the HGMD into phenotypes as defined in the HPO (Kohler et al., 2014) . The HPO was downloaded from https://human-phenotype-ontology.github.io/downloads.html, including 11,785 HPO phenotypes. A total of 2,572 diseases with 124,452 annotated mutations were mapped to HPO. The number of mutations associated with a disease ranges from 1 to as high as 20,685 for abnormalities of nervous system morphology, with an average of 16 mutations per disease and a median of 2. After including mutations assigned to subclasses of diseases, the average number increased to 48 and the median to 18. We compared disease pairs containing at least five common mutations, and this leads to 42, 083 pairs.
Brain disorders dataset
The genetic relationships of five psychiatric diseases and eight neurological diseases were obtained from a recent study carried out by the Brain Storm consortium . These 13 diseases have 48 pairs sharing mutations in the HGMD database.
DisGeNET dataset
In order to compare with a gene-based method, we downloaded the DisGeNET (Pinero, et al., 2015) , which collected 17,381 genes and their 15,093 relevant phenotypes by integrating several public data sources and literature, and clinical or abnormal human phenotypes. Of these, 11,103 disease phenotypes were mapped to the HPO, and 927 diseases were found to overlap with the diseases in the HGMD dataset.
To use this dataset in assessing the prediction of associated mutations, we retained those diseases (445 diseases) associated with > 20 mutations. These diseases were associated with 14,085 genes from the DisGeNET, and 5,102 genes harboring 122,191 genetic mutations from the HGMD.
Evaluating genetic similarity between diseases
We evaluated genetic similarity between diseases by the number of shared mutations through the exact binominal test. Mutations were assigned to a disease if they associated with either the disease itself or its descendant phenotypes according to the hierarchical relationships of diseases as defined in HPO. For two diseases, A and B are associated with m mutations and n mutations, respectively. The chance of one mutation related with disease A in all mutations existed in the database is m/N, where N is the total number of mutations in the HGMD. Thus, the expected number of mutations shared by both A and B is m × n/N.
We excluded pairs of diseases where one disease was a descendant of the other.
Clustering diseases according to ICD-10 ID
Diseases that shared mutations were mapped onto the disease clusters defined by ICD-10. ICD-10 is the 10th version of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list drawn up by the World Health Organization (WHO). ICD-10 contains 22 disease "Chapters" that are divided into 263 disease "blocks" and 12,131 disease "codes." In this study, the HPO IDs were mapped to disease "Chapters."
Evaluating disease relations by cell-specific expression profiles
The FANTOM5 (Lizio et al., 2015) human gene expression data cover a diverse range of 889 cellular states and assess the promoter activity of every known gene in each cell or tissue type. We downloaded the human CAGE peak data qualified by transcripts per million (https://fantom.gsc.riken.jp/5/datafiles/latest/extra/CAGE_peaks/hg 19.cage_peak_tpm_ann.osc.txt.gz). In this file, the terms describing cell types were queried in "Medical dictionary for Regular activity (MedDRA R )" to obtain "Cui" IDs that were subsequently mapped to HPO IDs. This led to 64 unique HPO IDs including 48 cancers. The expression peaks assigned to each gene were averaged over multiple experiments for the same cell type, which yielded an estimated aggregate expression value for each gene in each cell type (disease). A gene was considered to be enriched (over-expressed) in a single cell type if the gene expression was at least n (5, 7, or 10)-fold higher in that cell type than the average over all other cell types in the dataset (Yu et al., 2015) .
We measured disease relations according to the number of overlapping over-expressed genes in cells. For each pair of diseases, the expected number of overlapping over-expressed genes by chance would be m × n/N, where m and n are the numbers of over-expressed genes in two cell types, respectively; N is total number of genes (24, 383, RefSeq gene information [hg19] ) in the human genome (Zhao et al., 2016) . The overexpression similarity was evaluated by the exact binomial test.
Predicting novel mutations according to genetic similarity across diseases
A cross-validation test was performed to assess how well diseasecausing mutations from a particular disease can be inferred from known mutations associated with genetically similar diseases. For each query disease, we mapped mutations to genes, and randomly divided all of genes into 10 folds to ensure mutations within a gene will not be separated into both test and training sets to avoid potential overtraining. Each time, mutations from nine folds of genes were employed as training set to calculate the genetic similarity with all other diseases. Similar to a previous study (Zhao, Nyholt, Yang, Wang, & Yang, 2017) , we have scored a mutation by S (m j ) = ∑ i i i,j , where i is a converted Chi-square with one degree of freedom from the P value of a relevant disease i, and i,j is 1.0 only if mutation j is predicted to be associated with disease i, and is 0, otherwise. This is an empirical formula to score mutations. We converted P values to the Chisquare distribution with one degree of freedom so that the scores can be summed over diseases. Mutations existing in the training set were excluded for testing. All mutations above a given threshold were predicted to be associated with the disease, while the others were not. 
Discriminating Crohn disease-susceptible individuals from healthy persons
We further utilized the mutation-based genetic similarity approach The performance of each method was assessed by the area under the receiver operating characteristic curve (AUC).
RESULTS
Pairwise genetic similarity between human diseases
We measured pairwise genetic similarity between two diseases according to the statistical significance (the lower P value means the more similar disease pairs) in the sharing of disease-causing mutations as compared with random chance. This method was termed DRAM. For comparison, we also mapped the mutations to genes, and assessed genetic similarity according to the number of overlapping genes (namely DRAG, Disease RelAtionship by shared Genes).
We assessed disease-disease relations for a total of 42,083 disease pairs in 2,572 diseases successfully mapped to HPO (see Methods). By using a binomial test P value cutoff of 0.05, DRAM detected 17,514 related disease pairs (41.6%) involving 2,100 diseases (81.6%). Among these, 5,332 pairs (13%) show a significant sharing of mutations with P value < 1.2 × 10 −6 (0.05/42083) after Bonferroni correction. In comparison, DRAG generated 25,692 related pairs with P value < 0.05 and 6,027 pairs with P value < 1.2 × 10 −6 . The smaller number of related pairs of diseases identified by the DRAM is as expected because sharing exactly the same mutation is a much stricter requirement than simply sharing the same gene. However, the disease-disease relationships ascertained from DRAM only moderately correlates with those from DRAG in terms of its significance (Spearman's correlation coefficient
[SPC] = 0.47, P value is < 2.6 × 10 −6 ). The correlation is slightly better (SPC = 0.52) for 14,288 related disease pairs (P value < 0.05) commonly detected by both DRAG and DRAM.
Genetic correlation between brain disorders according to shared heritability and shared mutations
To assess our methods, we compared disease relationships based upon shared mutations (DRAM) with those based upon shared genes (DRAG) as well as those based on shared heritability in common brain diseases. SPC between heritability-based and mutation-based disease-disease relationships (from DRAM) is higher (SPC = 0.505, P value = 2.5 × 10 −4 ) than that from DRAG (SPC = 0.343, P value = 7.7 × 10 −3 ). To examine the significance of the difference, we Supp. Figure S2 .
F I G U R E 1 Mutation-similarity network reveals relationships in brain diseases. Disease-disease relationship networks in eight neurological diseases (rectangle nodes) and five psychiatric diseases (ellipse nodes), assessed through sharing mutations by DRAM and sharing heritability in a previous study. The connecting edges are disease pairs with significant genetic similarity (P value < 0.05/48, 1.0 × 10 −3 ) detected both by DRAM and by heritability (dash line), by DRAM but not by heritability (solid), and by heritability but not by DRAM (dot line). F, seizures stands for focal seizures; G, seizures-generalized seizures; I, stroke-ischemic stroke; SCZ, schizophrenia; BPD, bipolar disorder; MDD, major depressive disorder; ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder
When an adjusted P value cutoff of 1.0 × 10 −3 ( = 0.05/48) was used, 22 and 12 out of 48 pairs were detected as related by DRAM and the heritability-based estimation, respectively. Of the 12 most significantly related pairs by DRAM, nine pairs overlapped with those obtained by the heritability-based approach, which was a significant enrichment (P value = 2.8 × 10 −3 ) over pairs not showing relationships according to DRAM. Meanwhile, DRAM discovered 13 related pairs that were not revealed by the heritability-based approach as listed in Supp. Table S1 . The enrichment is significantly higher than the disease pairs sharing of genes. a Percentages of disease pairs with significant sharing of highly expressed genes among the 45 pairs with significant sharing of mutations detected by DRAM. b Percentages of disease pairs with significant sharing of highly expressed genes among the 1,363 pairs without significant sharing of mutations detected by DRAM. c Binominal test results on difference between two percentages of disease pairs showing significant sharing of highly expressed genes among those with and without significantly sharing mutations as detected by DRAM. d Percentages of disease pairs with significant sharing of highly expressed genes among the 58 disease pairs with significant sharing of genes by DRAG. e Binomial test results on difference between two percentages of disease pairs showing significant sharing of highly expressed genes among disease pairs significantly sharing mutations (by DRAM) and significantly sharing genes (by DRAG).
F I G U R E 2 DPOE (Disease Pairs with significant sharing of Over-Expressed) genes are enriched with disease pairs with significant sharing of mutations. Each node is a disease shape-coded in terms of its affected cell type. Sixty-two DPOE genes by 5-, 7-, or 10-fold are compared with the pairs with significant sharing of mutations. Larger nodes indicate a disease sharing mutations with more diseases. The thin edges represent disease pairs (only 17 pairs) not detected to be related (P value > 0.05) by DRAM, whereas the thick edges (45 pairs) represent disease pairs sharing overexpressed genes and mutations significantly at the same time. Different cell types affected by diseases were shown in different shapes as labeled
Related diseases identified by DRAM showing significant sharing of over-expressed genes
If two diseases are related, it is reasonable to suppose that these two diseases might share over-expressed genes. We defined overexpressed genes using three different thresholds (5, 7, or 10-fold higher than the average levels in all tissues as described in the Methods section). As shown in Table 1 , 82%, 89%, and 80% pairs in 45 related disease pairs detected by DRAM were found to share significantly greater number of over-expressed genes than by random expectation under three thresholds, respectively (all P values < 1.6 × 10 −4
by binomial test). They were also significantly higher than 49%, 50%, and 53% in 1,363 unrelated disease pairs as defined by DRAM (P values < 2 × 10 −4 ).
In order to indicate whether the agreement is due to bias of specific cell types, we built the disease-disease connections based on significant sharing of over-expressed genes and significant sharing of muta- and leukemia) significantly share mutations with six diseases, respectively. These results potentially showed that shared mutations located in key driver genes causing multiple cancers or other diseases by influencing gene expression.
As a comparison, DRAG identified 58 related disease pairs based on the same threshold (P ≤ 0.05) for defining disease-disease relationships. However, only 52%, 58%, and 54% of disease pairs were found to significantly share over-expressed genes according to three thresholds for defining over-expression. These percentages are significantly lower than those yielded by DRAM (Table 1) , but not significantly (with all P values > 0.1) different from the percentages in unrelated pairs as ascertained by DRAG in Supp. Table S2 .
When selecting the same number of top significant disease pairs for both DRAG and DRAM, 35 out of 45 pairs by DRAG were indicated as significantly sharing over-expressed genes. In comparison with 40 pairs by DRAM, DRAG has missed six pairs and identified one new pair.
Predicting novel mutations from mutations associated with relevant diseases
The ability to predict novel mutations by DRAM was compared with DRAG methods based on either the HGMD database or the DisGeneT database. As shown in Figure 3A , DRAM achieved the highest aver-
age MCC values for all diseases by 10-fold cross-validation. DRAG based on HGMD was found to exhibit higher performance than DRAG based on the DisGeneT database. This is likely because DisGeneT acquired gene-disease associations from multiple databases, which may be inconsistent with each other. Individually, DRAM achieved
higher MCC values than DRAG (HGMD) in 245 out of 445 diseases (55%). It also achieved higher MCC values than DRAG (DisGeneT) in 304 (304 out of 445, 68%) diseases. Application of the pairwise t-test indicated that these differences were both significant (P value = 0.04 and 3.1 × 10 −11 , respectively). This trend was confirmed by EFs in top ranked predicted mutations (0.1%, 0.5%, and 1% predictions) in Figure 3B . For example, DRAM represents an improvement over DRAG (HGMD) by 24% for EFs in the top-ranked 0.1% predictions (Table 2) . On average, DRAM has a sensitivity of 44.3% for all predicted mutations, as compared with 42.6% sensitivity by DRAG (HGMD), and 40.3% sensitivity by DRAG (DisGeneT). DRAM represents an improvement over DRAG (HGMD and DisGeneT) in terms of sensitivity.
As an example, we tested our method on peripheral arterial disease (PAD) that was indicated relevant to 1,307 mutations by HGMD.
These mutations were mapped to 101 genes. From these genes, we randomly selected 91 genes (90% training set) mapped by 1,055 mutations to detect diseases related with PAD and to predict mutations causing PAD. The performance of the prediction was evaluated by counting the predicted mutations consistent with the remaining 252 mutations (test set). As a result, 13 diseases were found to exhibit significant sharing of mutations with PAD. These 13 related diseases contained 1,298 unique mutations that were scored according to genetic similarity between these diseases with PAD (described in Methods).
In the top ranked 124 mutations (0.1% all human mutations), there 
Identifying individuals susceptible to Crohn disease
Although the overall precision in predicting novel mutations was only moderate, these predicted mutations are nevertheless useful for assisting disease diagnostics. To demonstrate this, we employed DRAM to identify individuals susceptible to Crohn disease. As described in 
F I G U R E 5
The consistency between phenotypic and mutationbased clustering. There are 296 mutation-sharing disease connections (in gray) between 19 phenotypic chapters classified by ICD-10. Each node represents one disease phenotypic chapter detailed in Supp. Table S3 . The width of the edge represents the median -log(P) [P:
genetic similarity] between diseases within two chapters. The most significant association within a single chapter (in a loop) or between the chapters (in a line) is shown in black. Eleven loops in black indicate the strongest association within the chapter itself
DISCUSSION
In this study, we systematically quantified genetic similarity across 2,572 human inherited diseases according to the extent of sharing of disease-causing mutations between diseases. This study was made possible by the availability of a comprehensive collection of diseasecausing mutations represented by the HGMD and the hierarchical definitions of diseases by the HPO. We showed that disease-disease relations are more accurately described by shared specific mutations than by shared disease-causing genes based on multiple independent tests. This includes consistency with genetic correlation in brain diseases according to shared heritability, the sharing of over-expressed genes in different diseases, an improvement in predicting novel diseasecausing mutations by 10-fold cross-validation, and more accurate discrimination of Crohn disease-susceptible individuals from healthy individuals.
Shared genes are commonly employed for building disease-disease relationships (Chen, Bardes, Aronow, & Jegga, 2009; Goh et al., 2007) .
Inferring disease-disease relationships by shared mutations is a much stricter criterion than by shared genes. This is because shared mutations automatically imply shared genes, but not vice versa. The low correlation between disease relationships detected by DRAM and DRAG highlights the importance of using mutation-based inference, rather than gene-based inference, for revealing disease-disease associations.
We compared DRAM with heritability-based method in assessing disease similarity. Heritability is calculated by correlating the estimated heritability of the phenotypes from all SNP associations, and majority of SNP associations are non-significant and contributed to the calculation. DRAM is purely based on mutations related with diseases.
It unlikely includes the relationships that the shared heritability study captured. Moreover, most SNPs used by the heritability method are not included by DRAM. Thus, a heritability-based method is not necessarily more correlated with DRAM than DRAG.
We have demonstrated that DRAM is useful for identifying diseasedisease relationships. When DRAM was applied to 48 brain disease pairs, a significant number of overlapping mutations were found between ASD and ADHD. This result is consistent with the observation that ADHD and ASD exhibit behavioral overlaps accompanied by abnormalities in similar brain systems (Lim et al., 2014; Polderman, et al., 2014; Reilly, Senior, & Murtalgh, 2014) . The similarities between diseases as revealed by DRAM are also reflected in the overlap of their clinical features. For example, the relationship of ischemic strokes (I. Stroke) and migraine with aura, identified by DRAM but missed by heritability, is consistent with the fact that ischemic strokes can be miscategorized as cerebral infarction during the course of a typical migraine with aura attack (Lee, Lee, & Chung, 2016) . The relationship between migraine and focal epilepsy concurs with the fact that both diseases can be associated with cortical spreading depression, a wave of profound cellular depolarization (Rogawski, 2012) . Moreover, genetic similarity between Alzheimer disease and psychiatric diseases may reflect a shared cognitive effect spectrum. For example, MDD may be observed in the early stage of Alzheimer disease (Niida, Niida, Kuniyoshi, Motomura, & Uechi, 2013) , and Alzheimer disease shares some of the same symptoms with late onset bipolar disorder (Besga et al., 2015; Lebert, Lys, Haem, & Pasquier, 2008) . Future studies that aim to connect both overlapping mutations and overlapping clinical features across diseases could reveal additional insights into underlying molecular mechanisms.
Another useful application of DRAM lies in its ability to disclose potential disease-causing mutations from the comparison of genetically related diseases. This is evident from the 10-fold crossvalidation using annotated disease-causing mutations in HGMD as well as the improved identification of Crohn disease-susceptible individuals through consideration of predicted disease-causing mutations. The overall low accuracy is likely because only a relatively small number of disease-causing mutations have so far been identified in the majority of heritable diseases. As more and more disease-causing mutations are discovered, we expect that DRAM will become even more powerful in uncovering both novel disease-disease relationships and diseasecausing mutations, and therefore has the potential to aid disease diagnosis.
We further tested the disease relationship by clustering diseases according to ICD-10 IDs, and built an association network of 19 disease chapters. The disease chapters of ICD-10 were based on the phenotypic characteristics of diseases (2010). As shown in Figure 5 , we found that most (11 out of 19) disease clusters showed the closest relatedness with themselves based on shared mutations, which reflected consistency between the genetic and phenotypic similarity between diseases.
To test the significance of this observation, we have generated 42,086 random disease pairs and mapped them to ICD-10 for 1,000
times, and in all random datasets there are less than 11 clusters (the maximum observed value is 4) showing higher similarity to themselves than others. Thus, the P value is < 1 × 10 −3 . On the other hand, the Figure S3 ). "Morphological abnormality of the central nervous system" has 62 connections within the chapter but 46
connections to diseases in other chapters.
CONCLUSIONS
We have systematically quantified disease-disease relationships by sharing of mutations. Our results demonstrated that disease-disease relationships based on sharing of mutations are more accurate to predict disease-causing mutations and to discriminate Crohn disease susceptible individuals when compared to those based on sharing of genes. We also show that the detected disease-disease relationships are mostly consistent with phenotypic relationships.
